Patient Experience with the SensoReady^® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease

References

• Kuek A, Hazleman BL, Ostor AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260. doi:10.1136/pgmj.2006.052688
   PubMed Web of Science ®Google Scholar
• McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680–686. doi:10.1038/s41577-021-00603-1
   PubMed Web of Science ®Google Scholar
• Humphry N. The efficacy of anti-TNFs in immune-mediated disease. EMJ Gastro. 2022;115:2–9. doi:10.33590/emjgastroenterol/10102824
   Google Scholar
• Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18(1):19–40. doi:10.1038/nrd.2018.183
   PubMed Web of Science ®Google Scholar
• van den Bemt BJF, Gettings L, Domańska B, et al. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384–392. doi:10.1080/10717544.2019.1587043
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619–1629. doi:10.1016/j.clinthera.2006.10.006
   PubMed Web of Science ®Google Scholar
• Liu Y, Söderberg J, Chao J. Adherence to and persistence with adalimumab therapy among Swedish patients with Crohn’s disease. Pharmacy (BaseI). 2022;10(4):87. doi:10.3390/pharmacy10040087
   PubMed Web of Science ®Google Scholar
• Vermeire S, D’Heygere F, Nakad A, et al. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Prefer Adherence. 2018;12:1193–1202. doi:10.2147/PPA.S154181
   PubMed Web of Science ®Google Scholar
• Fenwick S, Thakur K, Munro D. Nurse and patient perceptions and preferences for subcutaneous autoinjectors for inflammatory joint or bowel disease: findings from a European survey. Rheumatol Ther. 2019;6(2):195–206. doi:10.1007/s40744-019-0144-8
   PubMed Web of Science ®Google Scholar
• Ridyard CH, Dawoud DMM, Tuersley LV, Hughes DA. A systematic review of patients’ perspectives on the subcutaneous route of medication administration. Patient. 2016;9(4):281–292. doi:10.1007/s40271-015-0160-x
   PubMedGoogle Scholar
• Ross AP, Besser C, Naval S, et al. Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey. BMC Neurol. 2023;23(1):85. doi:10.1186/s12883-023-03100-1
   PubMed Web of Science ®Google Scholar
• Thakur K, Biberger A, Handrich A, Rezk MF. Patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a patient survey in Europe. Rheumatol Ther. 2016;3(2):245–256. doi:10.1007/s40744-016-0048-9
   PubMed Web of Science ®Google Scholar
• Tischer B, Mehl A. Patients’ and nurses’ preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adherence. 2018;12:1413–1424. doi:10.2147/PPA.S169339
   PubMed Web of Science ®Google Scholar
• Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42(3):387–391. doi:10.1136/gut.42.3.387
   PubMed Web of Science ®Google Scholar
• Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MND. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6(2):65–77. doi:10.1177/2040622314563929
   PubMed Web of Science ®Google Scholar
• Palm Ø, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population‐based study (the IBSEN study). Rheumatology (Oxford). 2001;40(11):1256–1261. doi:10.1093/rheumatology/40.11.1256
   PubMed Web of Science ®Google Scholar
• Health Canada. HYRIMOZ Product monograph; 2022. Available from: https://pdf.hres.ca/dpd_pm/00067757.PDF. Accessed April 5, 2024.
   Google Scholar
• Health Canada. HUMIRA Product monograph; 2022. Available from: https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/HUMIRA_PM_EN.pdf. Accessed April 5, 2024.
   Google Scholar
• GI Society. Provincial and Territorial Biologics Policies; 2022. Available from: https://badgut.org/information-centre/a-z-digestive-topics/provincial-biologics-policies/#:~:text=Phase%204%3A%20On%202021%2D04,Brenzys%C2%AE%20and%20Erelzi%C2%AE. Accessed April 5, 2024.
   Google Scholar
• Lacour J-P, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847–856. doi:10.1111/jdv.14073
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour J-P, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090. doi:10.1111/jdv.12751
   PubMed Web of Science ®Google Scholar
• Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47. doi:10.1186/s13075-018-1551-x
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018;35(9):1333–1355. doi:10.1007/s12325-018-0759-0
   PubMed Web of Science ®Google Scholar
• Cross MJ, March LM, Lapsley HM, Byrne E, Brooks PM. Patient self-efficacy and health locus of control: relationships with health status and arthritis-related expenditure. Rheumatology (Oxford). 2006;45(1):92–96. doi:10.1093/rheumatology/kei114
   PubMed Web of Science ®Google Scholar
• Schmalzing M, Zinke S, Schnorfeil M, et al. Use of a self-injection assessment questionnaire to assess patient satisfaction with a self-injection device in rheumatoid arthritis patients receiving SDZ-ETN (GP2015) in Germany: an interim analysis of the real-world COMPACT study. Abstract presented at 48. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 34. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh). September 9–12; 2020; virtual.
   Google Scholar
• Schmalzing M, Askari A, Sheeran T, et al. Outcomes of the Self-Injection Assessment Questionnaire in rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis patients receiving GP2015 (etanercept biosimilar) in a real-world study: final results from COMPACT study. Abstract AB0419, presented at European Alliance of Associations for Rheumatology (EULAR) 2023 Congress. May 31–June 3; 2023; Milan, Italy.
   Google Scholar
• Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7(1):35–64. doi:10.1007/s40744-019-00190-7
   PubMed Web of Science ®Google Scholar
• Taylor PC, Gonzalez YS, Clark R, Faccin F, Howell O. Outcomes following adalimumab bio-originator to biosimilar switch-A comparison using real-world patient- and physician-reported data in European countries. Rheumatol Ther. 2023;10(2):433–445. doi:10.1007/s40744-022-00526-w
   PubMed Web of Science ®Google Scholar
• Ross AP, Nicholas J, Tai MH, et al. Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis. Poster LB09, presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023. May 31–June 3; 2023; Aurora, CO, USA.
   Google Scholar
• Brouwer R, Ten Klooster PM, Masselink JB, Vonkeman HE. Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: an observational study in rheumatoid arthritis patients. Pharmacol Res Perspect. 2022;10(6):e01025. doi:10.1002/prp2.1025
   PubMed Web of Science ®Google Scholar
• Bruni C, Gentileschi S, Pacini G, et al. Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211033679. doi:10.1177/1759720X211033679
   PubMed Web of Science ®Google Scholar
• Nabi H, Georgiadis S, Loft AG, et al. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Ann Rheum Dis. 2021;80(11):1400–1409. doi:10.1136/annrheumdis-2021-219951
   PubMed Web of Science ®Google Scholar
• van Adrichem RCS, Voorneveld HJE, Waverijn GJ, Kok MR, Bisoendial RJ. The non-medical switch from reference adalimumab to biosimilar adalimumab is highly successful in a large cohort of patients with stable inflammatory rheumatic joint diseases: a real-life observational study. Rheumatol Ther. 2022;9(4):1109–1118. doi:10.1007/s40744-022-00465-6
   PubMed Web of Science ®Google Scholar